Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
RNXT
SellHot AirRenovoRx, Inc. · Healthcare · United States · $75M · Avg Vol: $2M/d
26
StockRankGet insider-trade alerts
Q
26
V
21
M
66
P/E (TTM)
—
ROE
-125.2%
D/E
0.0x
Dividend %
—
COMPANY DESCRIPTION
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 43.0K | 1.1M | 2511.6% | 2.0M | 3.9M | 11.4M | 219.1% |
| EPS | -0.22 | -0.23 | -0.40 | -0.32 | — | -0.31 | -0.27 | -0.12 | — |
| Shares | 45.1M | 45.1M | 24.0M | 36.6M | -18.9% | 45.1M | — | — | — |
| Debt | — | 0 | 0.3M | 0.2M | -23.7% | 0.4M | — | — | — |
| Equity | 6.2M | -3.0M | 4.5M | 5.4M | -4.2% | — | — | — | — |
| Op CF | -8.8M | -10.3M | -9.1M | -11.0M | — | -11.9M | — | — | — |
| Inv CF | -2.0M | 2.0M | -12.0K | -2.0K | — | — | — | — | — |
| Fin CF | 42.0K | 5.0M | 15.1M | 10.8M | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)+88.1%
SMA 50SMA 200
Close
$1.77
RSI (14)
60.5
52W High
$2.59
From 52W High
0.7%
SCORE BREAKDOWN
Quality
26
ROIC
-209.8%2.5
ROE
-125.2%7.1
GP/Assets
20.6%46.1
Op. Margin
-368.4%11.1
FCF/Assets
-135.6%1.2
Piotroski
316.0
Int. Cover
—N/A
D/E Ratio
0.04x72.8
Current Ratio
5.74x76.0
Value
21
P/E (TTM)
—N/A
EV/EBITDA
-7.6x25.0
P/FCF
—N/A
P/B
12.0x9.8
P/S
54.6x9.0
Div Yield
—N/A
Momentum
66
52W High %
68%48.3
RS 6M
110%97.8
SMA 50/200
1.23x90.1
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
+61%61.5
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$75M
P/E (Forward)
-19.9x
Gross Margin
84.4%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of RNXT are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| RNXT | RenovoRx, Inc.(you) | $75M | 26 | Sell |
| APLM | Apollomics, Inc. | $77M | 28 | Sell |
| XBIT | XBiotech Inc. | $69M | 27 | Sell |
| MNOV | MediciNova, Inc. | $71M | 23 | Sell |
| PTHS | Pelthos Therapeutics Inc. | $95M | 26 | Sell |
| ACET | Adicet Bio, Inc. | $85M | 23 | Sell |
| CSBR | Champions Oncology, Inc. | $68M | 30 | Sell |
| ACRV | Acrivon Therapeutics, Inc. | $88M | 29 | Sell |
| ATRA | Atara Biotherapeutics, Inc. | $92M | 23 | Sell |
| NRXS | NeurAxis, Inc. | $75M | 18 | Strong Sell |
Peer medians: ROE -30.2% · P/E 27.0x · Gross margin 58.1%